SVRA Savara Inc.
USHealthcareAs of 2026-07-08 16:00
Why SVRA matters now
Savara Inc. (SVRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.38 with +2.74% on the session and $1.31B in market capitalization; recent performance reads 1-month +16.53% and YTD -8.79%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-37.3M, and EPS of $-0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.5%.
The latest indexable market news headline is "What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Lowrance David L filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.91
P/S
0.00
EV/EBITDA
-8.65
DCF Value
$-0.00
FCF Yield
-9.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-87.2%
ROA
-58.4%
ROIC
-65.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-37.3M | $-0.15 |
| Q4 2025 | $0.00 | $-32.2M | $-0.13 |
| FY 2025 | $0.00 | $-118.8M | $-0.53 |
| Q3 2025 | $0.00 | $-29.6M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.27
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.